<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><description>领星是由中美生物医学数据科学家携手高年资肿瘤专家共同开创的临床科技和数据平台，提供肿瘤精准医疗和数据智能服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 20 May 2021 11:37:05 +0800</pubDate><image><url>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</url><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>预告丨领星与安捷伦强强联合，探讨捕获测序在肿瘤精准医疗和研究中的应用</title><link>https://mp.weixin.qq.com/s/FOd-gRhQHbc4q8xxuw1H9w</link><description></description><content:encoded><![CDATA[预告丨领星与安捷伦强强联合，探讨捕获测序在肿瘤精准医疗和研究中的应用]]></content:encoded><pubDate>Thu, 20 May 2021 11:28:28 +0800</pubDate></item><item><title>速递丨转移性乳腺癌新药！卫材公布Halaven真实世界研究强劲疗效数据</title><link>https://mp.weixin.qq.com/s/-4fQL6AAK1PUFnk00BCq3A</link><description></description><content:encoded><![CDATA[速递丨转移性乳腺癌新药！卫材公布Halaven真实世界研究强劲疗效数据]]></content:encoded><pubDate>Thu, 20 May 2021 11:28:28 +0800</pubDate></item><item><title>临床试验丨 肝癌（五）</title><link>https://mp.weixin.qq.com/s/Ke5iQ2TBXN-o4sBUW1fH3A</link><description></description><content:encoded><![CDATA[临床试验丨 肝癌（五）]]></content:encoded><pubDate>Wed, 19 May 2021 11:21:00 +0800</pubDate></item><item><title>纳武单抗能用于食管癌及胃食管癌术后辅助化疗吗？</title><link>https://mp.weixin.qq.com/s/h9UIIXFa_nrGDzWPBkwxfA</link><description></description><content:encoded><![CDATA[纳武单抗能用于食管癌及胃食管癌术后辅助化疗吗？]]></content:encoded><pubDate>Tue, 18 May 2021 16:32:38 +0800</pubDate></item><item><title>速递丨云顶新耀戈沙妥组单抗(Trodelvy)上市申请获国家药监局受理!</title><link>https://mp.weixin.qq.com/s/i4YUmL94VhYjiP8hqPuw5g</link><description></description><content:encoded><![CDATA[速递丨云顶新耀戈沙妥组单抗(Trodelvy)上市申请获国家药监局受理!]]></content:encoded><pubDate>Tue, 18 May 2021 16:32:38 +0800</pubDate></item><item><title>一文梳理CAR-T 细胞治疗多发性骨髓瘤临床应用证据</title><link>https://mp.weixin.qq.com/s/k9gVGFCAz1jxxpXc-umjgA</link><description></description><content:encoded><![CDATA[一文梳理CAR-T 细胞治疗多发性骨髓瘤临床应用证据]]></content:encoded><pubDate>Thu, 13 May 2021 11:48:17 +0800</pubDate></item><item><title>速递丨Nat Med：揭示乳腺癌免疫治疗作用机制并提出预测疗效新方法</title><link>https://mp.weixin.qq.com/s/CNs2ielMhaRIWj9Q_7qTsg</link><description></description><content:encoded><![CDATA[速递丨Nat Med：揭示乳腺癌免疫治疗作用机制并提出预测疗效新方法]]></content:encoded><pubDate>Thu, 13 May 2021 11:48:17 +0800</pubDate></item><item><title>临床试验丨 肝癌（四）</title><link>https://mp.weixin.qq.com/s/1msE45Ba-JmSxhJI05nWXQ</link><description></description><content:encoded><![CDATA[临床试验丨 肝癌（四）]]></content:encoded><pubDate>Wed, 12 May 2021 07:54:57 +0800</pubDate></item><item><title>液体活检监测MRD为何如此重要？</title><link>https://mp.weixin.qq.com/s/TApCEh3TDhs09r5Eg7xdvg</link><description></description><content:encoded><![CDATA[液体活检监测MRD为何如此重要？]]></content:encoded><pubDate>Tue, 11 May 2021 18:25:34 +0800</pubDate></item><item><title>速递丨博安生物贝伐珠单抗注射液在华获批上市</title><link>https://mp.weixin.qq.com/s/x51ZGYPHtvzgkH4oRWJUZg</link><description></description><content:encoded><![CDATA[速递丨博安生物贝伐珠单抗注射液在华获批上市]]></content:encoded><pubDate>Tue, 11 May 2021 18:25:34 +0800</pubDate></item><item><title>AACR 2021丨结直肠癌患者临床病理与免疫疗效的相关性</title><link>https://mp.weixin.qq.com/s/ZukA3lcLaNtYFq0bC6m-1A</link><description></description><content:encoded><![CDATA[AACR 2021丨结直肠癌患者临床病理与免疫疗效的相关性]]></content:encoded><pubDate>Sat, 08 May 2021 09:48:43 +0800</pubDate></item><item><title>终于明白MSI-H/dMMR 肿瘤是什么了！</title><link>https://mp.weixin.qq.com/s/5yMaISPPzks0EPTDfeZZzA</link><description></description><content:encoded><![CDATA[终于明白MSI-H/dMMR 肿瘤是什么了！]]></content:encoded><pubDate>Thu, 06 May 2021 15:30:51 +0800</pubDate></item><item><title>速递丨全球首个CD38单抗新适应症在华获批！</title><link>https://mp.weixin.qq.com/s/X8YTkcWr_tQpADlQAeKqFg</link><description></description><content:encoded><![CDATA[速递丨全球首个CD38单抗新适应症在华获批！]]></content:encoded><pubDate>Thu, 06 May 2021 15:30:51 +0800</pubDate></item><item><title>精益求精，远超“指引”的8道质控，让领星更可靠！</title><link>https://mp.weixin.qq.com/s/7jkpIZYeopPpbG8LCpl3BQ</link><description></description><content:encoded><![CDATA[精益求精，远超“指引”的8道质控，让领星更可靠！]]></content:encoded><pubDate>Fri, 30 Apr 2021 16:28:03 +0800</pubDate></item><item><title>一文盘点 PARP 抑制剂临床证据</title><link>https://mp.weixin.qq.com/s/cLhukZRmZWXOi1mrcs3PqQ</link><description></description><content:encoded><![CDATA[一文盘点 PARP 抑制剂临床证据]]></content:encoded><pubDate>Thu, 29 Apr 2021 11:52:43 +0800</pubDate></item><item><title>速递丨恒瑞医药CDK 4/6抑制剂上市申请获受理；Nature：科学家发现癌症代谢新机制</title><link>https://mp.weixin.qq.com/s/GN10s8N5Gt7oOpRsvAt0Ow</link><description></description><content:encoded><![CDATA[速递丨恒瑞医药CDK 4/6抑制剂上市申请获受理；Nature：科学家发现癌症代谢新机制]]></content:encoded><pubDate>Thu, 29 Apr 2021 11:52:43 +0800</pubDate></item></channel></rss>